These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 26758560)

  • 1. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 4. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study.
    Smyth LM; Reichel JB; Tang J; Patel JAA; Meng F; Selcuklu DS; Houck-Loomis B; You D; Samoila A; Schiavon G; Li BT; Razavi P; Piscuoglio S; Reis-Filho JS; Taylor BS; Baselga J; Solit DB; Hyman DM; Berger MF; Chandarlapaty S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
    Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
    Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
    Thierry AR
    Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
    Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
    Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis.
    Koba H; Kimura H; Yoneda T; Sone T; Ohkura N; Hara J; Hosomichi K; Tajima A; Kasahara K
    Sci Rep; 2021 Apr; 11(1):8398. PubMed ID: 33863951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.